Merck, Cidara Therapeutics see US FTC grant early termination for $9.2bn deal
Merck and Cidara Therapeutics were granted early termination of the applicable Hart-Scott-Rodino Act waiting period by the US Federal Trade Commission on Friday, according to a securities filing. The $9.2 billion...To view the full article, register now.
Already a subscriber? Click here to view full article